Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: May 31, 2023

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Allogeneic T cells engineered with a bicistronic CD20xCD22 dual CAR and TALEN-mediated TRAC and CD52 knockouts killed B-cell lymphoma targets that carried either antigen alone or both. Against Raji and JeKo-1 lines the dual CAR lysed cells dose-dependently and kept killing through repeated tumor challenges every three days for up to 11 days, while single CD22 CAR T cells lost control of CD20-positive, CD22-negative cells. In disseminated Daudi and subcutaneous Raji models, doses of 1, 3 and 10 million CAR-positive cells cleared tumor and extended survival, and the cells persisted in bone marrow beyond 100 days. Sixteen of 21 primary B-NHL samples were killed with IFN-gamma release, and a…

Download Now →

Author: Beatriz Aranda-Orgilles, Isabelle Chion-Sotinel +10 more

Publications Other G-Rex®6 Well Plate

Publication Date: May 16, 2023

Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation

T cells carrying the chimeric engulfment receptor CER-1236, which joins the phosphatidylserine-binding TIM-4 domain to TLR2/TIR, CD28 and CD3ζ signaling, both kill tumor cells and engulf them. In vitro, CER-1236 T cells eliminated 87% of PS-exposing JeKo-1 mantle cell lymphoma cells within 120 h, and over 60% took up PS-coated beads. BTK or EGFR inhibitors raised surface PS on tumor cells and strengthened killing. In NSG mice, CER-1236 cleared REC-1 lymphoma in 11/11 animals with ibrutinib and 9/9 without it. In an NSCLC xenograft, osimertinib plus CER-1236 produced the largest tumor regression. After engulfing antigen-bearing tumor cells, CER-1236 T cells also activated E7-specific TCR T…

Download Now →

Author: Brandon Cieniewicz, Ankit Bhatta +16 more

Publications T-Cells G-Rex®10, G-Rex®100, G-Rex®100M

Publication Date: May 12, 2023

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

IMA101, an autologous multi-target T-cell therapy directed against up to four peptide-HLA cancer targets per patient, proved feasible and well tolerated in a first-in-human trial in advanced solid tumors. Of 214 patients screened, 43 completed leukapheresis, and 14 received T-cell products after fludarabine and cyclophosphamide lymphodepletion plus low-dose interleukin-2; some also received atezolizumab. Cytokine release syndrome was mild (grade 1 in six, grade 2 in four patients), with no neurotoxicity and no deaths in the first 100 days. No objective responses occurred, but three patients had disease stabilization lasting 7.3 to 13.7 months. Target-specific T cells reached up to 78.7% o…

Download Now →

Author: Apostolia M. Tsimberidou, Kerstin Guenther +39 more

Publications CAR T Cells, Treg Cells G-Rex®6 Well Plate

Publication Date: May 4, 2023

A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells

A chemically inducible IL-2 receptor signaling complex (CISC), built from FKBP–IL2RG and FRB–IL2RB fusion proteins, lets researchers select and expand gene-edited primary CD4+ T cells with rapamycin in place of IL-2. Placed at the FOXP3 locus, it enriched engineered Treg from under 20% edited cells to 40%–95% purity across five donors, and the cells showed Treg-like phenotype and suppressed effector T cells similarly to thymic Treg. In immunodeficient mice, rapamycin increased engraftment of CISC Treg without exogenous IL-2, and the dimerizer AP21967 improved GvHD outcomes at a subtherapeutic cell dose. A TRAC-targeted CD19-CAR version reached more than 70% CAR+ cells after 19 days of rap…

Download Now →

Author: Peter J. Cook, Su Jung Yang +12 more

Publications VST Cells G-Rex®100

Publication Date: May 3, 2023

Efficient ex vivo expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates

Rhesus macaque CD8-dominant T cells specific for HIV/SIV conserved elements can be expanded ex vivo from vaccinated animals, including SHIV-infected, ART-suppressed ones, and infused safely, though they did not persist or protect. Conserved-element DNA-vaccinated macaques donated 30-50 mL of blood; cells were stimulated with peptide-pulsed dendritic cells, then PHA blasts and irradiated GM-K562 feeders, and expanded in G-Rex® 100 flasks. Total viable cells rose a median 3-fold from day 0 to 11 and more than 5-fold from day 11 to 17, with no yield difference by SHIV status or ART. Products were nearly all CD8+ effector cells (median CD4:CD8 ratio 0.02). Two infused animals showed no differ…

Download Now →

Author: Sandra Dross, Rasika Venkataraman +13 more

Publications NK Cells

Publication Date: May 2, 2023

Process engineering of natural killer cell-based immunotherapy

Allogeneic natural killer (NK) cell therapy will need manufacturing processes that borrow from protein biologics production while treating the cells themselves as the final product. This review describes NK cell sources, including donor peripheral blood, cord blood, induced pluripotent stem cells and the NK-92 line, and the central role of engineered K562 feeder cells in expansion. Co-culture with K562/mbIL-21–4-1BBL feeder cells gave 10^4- to more than 10^6-fold expansion over 3–7 weeks. Current clinical-scale systems include bags, G-Rex® flasks and the CliniMACS Prodigy, whereas future scale may need 10–100 L stirred tanks, perfusion with cell retention, in-line sensing under process an…

Download Now →

Author: Pedram Motallebnejad, Anne Kantardjieff +3 more

Publications B Cells G-Rex®6 Well Plate

Publication Date: April 24, 2023

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus

Human monoclonal antibodies isolated from the only known survivor of Sosuga virus infection neutralize the virus potently, and antibodies against the attachment protein HN were generally stronger than those against the fusion protein F. Memory B cells from a leukapheresis sample taken five years after infection yielded 24 antibodies, 6 against HN and 18 against F. The HN antibodies all bound the globular head and fell into four competition groups. The F antibodies split into prefusion-specific, postfusion-specific and dual-reactive classes with eight competition groups. All but the single postfusion-specific antibody neutralized authentic virus, and rSOSV-24 reached an IC50 of 0.4 ng/mL.

Download Now →

Author: Helen M. Parrington, Nurgun Kose +11 more

Publications CAR T Cells G-Rex®6M Well Plate

Publication Date: April 12, 2023

Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models

Lowering the affinity of an EpCAM-directed CAR spared primary human epithelial cells but weakened tumor control in vivo, and adding NFAT-driven inducible IL-12 to the same construct restored anti-tumor activity. Alanine scanning of CDR-H3 in the UBS54 scFv identified Tyr6 as the critical residue, and substituting valine gave a KD of 10.8 μM against 0.88 ± 0.19 μM for the parent. In subcutaneous SNU-638 gastric xenografts in NSG mice given 1 × 10^7 T cells, Y6V-iIL-12 suppressed growth significantly better than Y6V alone, leaving about 60% of mice below 300 mm³. With an ICAM-1 CAR, F292A-iIL-12 made all mice tumor-free, 1 of 16 relapsing, and serum IL-12 stayed far below 1 ng/ml.

Download Now →

Author: Yanping Yang, Huan Yang +15 more

Publications Other

Publication Date: April 7, 2023

Current status of red blood cell manufacturing in 3D culture and bioreactors

Manufacturing red blood cells in vitro is a promising answer to donor-dependent blood shortages, but output remains below what a transfusion needs. A single adult unit requires more than 2×10^12 cells, which would take about 1,000 L of medium in conventional 2D culture at 2×10^6 cells/mL. This review compares cell sources (primary stem cells, iPSCs, immortalized erythroblast lines) and 3D approaches, including bone-marrow-mimicking scaffolds, hollow-fiber, wave-type, roller-bottle, spinner-flask, stirred-tank and gas-permeable bioreactors. Reported scale-ups reached up to 3 L stirred-tank cultures, and a 1 L gas-permeable system gave 3×10^7-fold erythroblast expansion with over 90% enucle…

Download Now →

Author: Soonho Kweon, Suyeon Kim +1 more

Publications Other

Publication Date: April 5, 2023

Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure

Combining a rapid interferon-gamma secretion enrichment with a 12-day short-term expansion can generate Aspergillus fumigatus-specific T cells from the same donor blood for immediate and sustained treatment of invasive aspergillosis. Of 320 healthy donors screened, 65% had IFN-γ-secreting Aspergillus-specific T cells after lysate stimulation. Magnetic enrichment gave a mean 49.6% IFN-γ+ among CD3+ cells with Asp-lysate versus 35.3% with a peptide-pool mixture (PepMix). Twelve-day expansion met the release criterion of more than 80 spots per 10^5 cells in all donors tested, with mean responses of 863 (lysate) and 833 (PepMix) spots. Expanded cells were mainly Th1-polarized CD4+ memory cell…

Download Now →

Author: Sabine Tischer-Zimmermann, Elisabeth Salzer +12 more

Publications CAR T Cells

Publication Date: March 31, 2023

CAR T-Cell therapy for the management of mantle cell lymphoma

This review summarizes how CAR T-cell therapy has been developed for relapsed or refractory mantle cell lymphoma (MCL), a B-cell malignancy that remains incurable. Brexucabtagene autoleucel (KTE-X19), a second-generation CD19-directed CAR T product, received USFDA approval on July 24, 2020 based on the ZUMA-2 trial. In ZUMA-2's efficacy cohort of 60 patients, the objective response rate was 93% with 67% complete responses; across all 74 treated patients it was 85% with 59% complete responses. Cytokine release syndrome occurred in 91% of patients, 15% at grade 3 or above. Limited tumor infiltration and limited trafficking remain barriers to successful CAR T-cell therapy.

Download Now →

Author: Zoufang Huang, Vivek P. Chavda +4 more

Publications CAR T Cells, T-Cells G-Rex®10, G-Rex®100

Publication Date: March 30, 2023

Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance

Inhibiting the tyrosine phosphatases PTP1B and TCPTP boosts T cell activity and adoptive T cell therapy more effectively than degrading CDK6. Cyclin D3/CDK6 phosphorylates both phosphatases, raising their activity and lowering tyrosine phosphorylation of CD3 zeta, which dampens T cell activation. In mouse and human T cells, blocking this axis increased IFN-gamma and granzyme B production and memory differentiation. It also raised killing of tumor cells by OT-I and CD19 CAR T cells in vitro. In a melanoma pmel transfer model, 4 of 9 mice given the PTP inhibitor with T cells were tumor-free at 11 weeks, versus 1 of 9 with the CDK6 degrader and 0 of 5 with T cells alone. No toxicity was obse…

Download Now →

Author: Xueliang Gao, Yongxia Wu +16 more